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ABSTRACT Tonsillectomy and adenoidectomy (T&A) is frequently performed in children with sickle
cell disease (SCD). Our aim was to evaluate the impact of this surgery on overnight oxygenation and rates
of complications in these patients.
Children with SCD who underwent T&A between 2008 and 2014 in two tertiary hospitals were
retrospectively evaluated. Overnight oximetry and admission rates due to vaso-occlusive pain episodes
(VOEs) and acute chest syndrome (ACS) in the year preceding and following the surgery were compared.
19 patients (10 males, 53%) with a median age of 6 years (range 3.5–8) were included. A significant
increase of mean overnight arterial oxygen saturation measured by pulse oximetry (SpO2) (from 93±3.6%
to 95.3±2.8%, p=0.001), nadir SpO2 (from 83.0±7.1% to 88±4.1%, p=0.004) and a reduction of 3% oxygen
desaturation index (from a median value of 5.7 to 1.8, p=0.003) were shown. The mean annual rate of
ACS decreased from 0.6±1.22 to 0.1±0.2 events per patient-year (p=0.003), while the mean cumulative rate
of hospitalisations for all causes and the incidence of VOEs were not affected.
T&A improved nocturnal oxygenation and was also associated with a reduction in the incidence of ACS
at 1-year follow-up after surgery.
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In children with SCD, this retrospective analysis suggests that tonsillectomy and adenoidectomy
may have a beneficial effect on nocturnal oxygenation level and the rate of ACS. This finding
will need further confirmation in prospective and larger studies. https://bit.ly/3gL6gaU
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Sickle cell disease (SCD) is the most frequent haemoglobinopathy with a global annual incidence of
300000 newborn cases [1]. SCD is characterised by acute and chronic manifestations, with progressive
organ damage and vasculopathy [2]. More specifically, deoxygenation leads to the formation of polymers
of haemoglobin S (HbS) that causes red blood cells (RBCs) sickling and increases their adherence to the
endothelium, resulting in vaso-occlusion and tissue hypoxia [2]. These mechanisms are the basis of
vaso-occlusive pain episodes (VOEs), as well as contribute to the pathogenesis of acute chest syndrome
(ACS) and other major complications [3].
Sleep-disordered breathing (SDB) with nocturnal hypoxaemia, including obstructive sleep apnoea (OSA),
is frequent in patients with SCD [4]. OSA is characterised by upper airway obstruction (partial or total)
that disrupts ventilation, causing haemoglobin desaturation and poor sleep quality [5]. The increased
prevalence of OSA and SDB in children with SCD is influenced by the high frequency of adenotonsillar
hypertrophy, which is likely to be a compensatory mechanism of the immune system to functional
hyposplenism [6, 7]. While it has been demonstrated that a low nocturnal haemoglobin oxygen saturation
(SpO2) in subjects with SCD is associated with cerebrovascular complications [8, 9], most recent prospective
studies did not find a significant association of low oxygen saturation with VOE and ACS [9, 10].
Tonsillectomy and adenoidectomy (T&A) is recommended for children with documented OSA and
adenotonsillar hypertrophy in the general paediatric population [11]. Few studies reported improved
overnight oxygenation in children with SCD and SDB undergoing T&A [12–14]; FARRELL et al. [12] also
showed a reduction in the hospital admission rate after T&A. However, the amount of available data
regarding the effect of T&A on the clinical course of SCD is still limited and further investigation is required.
This study tested the hypothesis that children with SCD undergoing T&A for obstructive SDB/OSA with
severe adenotonsillar hypertrophy had improved overnight oxygen saturation and decreased hospitalisation
rates for ACS and VOEs following the surgery.
Materials and methods
Medical records of children with SCD from two major tertiary hospitals (Evelina London Children’s Hospital
and King’s College Hospital, London, UK), who underwent T&A between 2008 and 2014, were retrospectively
evaluated. Data were collected within clinical audit report framework and routine quality improvement
analysis. Patients who had comparable overnight oximetry studies (TCM 4/40 monitoring system,
Radiometer®, software version 3.0, SpO2 averaging time 3 s) performed at steady state within 18 months before
and after the surgery, were included. Nocturnal oximetry was carried out at Evelina London Children’s
Hospital sleep laboratory over a single night, allowing the accompanying parent to stay in the same room with
the child and a sleep diary was recorded. Artefacts due to poor perfusion, low signal identification and
movement were manually excluded, as well as periods of wakefulness according to the sleep diary’s records.
Oximetry tests with less than 4 h of artefact-free data were excluded. Analysis software provided standard
parameters including overnight mean and nadir SpO2, 3% oxygen desaturation index (3% ODI) number of
validated desaturations of at least 3% per hour of sleep). In each participant the nocturnal oximetry tests
performed more closely to the surgery were compared. The presence of SDB was established according to
reported typical symptoms (e.g. loud snoring, witnessed apnoeas, restless sleep and mouth breathing). The
proportion of patients with a 3% ODI⩾3 at each data point was recorded, as the combination of SDB and 3%
ODI⩾3 was shown to be highly predictive of OSA in a retrospective cohort of paediatric patients [15].
Information on participants’ demographics, past medical history and peri-operative complications were also
taken from medical records. ACS was defined as the presence of fever and/or respiratory symptoms, plus a
new pulmonary infiltrate on a chest radiography [16], whereas a VOE was identified as an episode of acute
pain that lasted at least 4 h for which there was no explanation other than vaso-occlusion and that required
hospital admission with administration of parenteral opioids or nonsteroidal anti-inflammatory drugs [16].
The number of VOE and ACS episodes requiring hospitalisation and the total number of hospitalisations
in the 12 months before and after T&A were recorded in each patient.
Patients who started hydroxyurea (HU) therapy or chronic transfusion regimen in the 12 months before
and after T&A were excluded as these factors could affect the incidence of VOE and ACS [17], acting as
confounders in our analysis on of the impact of T&A on clinical outcomes. However, patients who had
been on HU or chronic transfusion for least 12 months prior to surgery were retained in the analysis as, in
this case, there was no other intervention, apart from T&A, introduced during the study period.
Statistical analysis
Continuous variables were expressed as mean or median (interquartile range). The mean annual rates of
VOE and ACS were defined as the average number of events per patient per year requiring hospital
https://doi.org/10.1183/23120541.00071-2020 2
PAEDIATRIC PULMONOLOGY | I. LIGUORO ET AL.
admission and were calculated for the year preceding and following the surgery. The mean annual rate of
“hospital admissions for all causes” was also calculated over the same time interval. All variables were
analysed for normality distribution (D’Agostino–Pearson omnibus normality test). Differences between
groups were evaluated by Wilcoxon matched-pairs signed-rank test (3% ODI, % time spent SpO2<90%)
and paired t-test (overnight mean SpO2, nadir SpO2, mean number of VOE, ACS and total hospitalisations
per patient per year). Fisher’s exact test was used to compare frequencies and percentages. A p-value ⩽0.05
was considered statistically significant. Statistical analyses were performed using GraphPad Prism version
8.4.2 for Windows (GraphPad Software, La Jolla, CA, USA; www.graphpad.com).
Results
General characteristics of the study population
47 children with SCD underwent T&A between 2008 and 2014. After excluding 7 patients who started HU
during the follow-up period, 3 who were treated with supplementary oxygen treatment at home in the year
after surgery because of persistent hypoxaemia and other 18 patients who had no comparable nocturnal
oximetry tests before and after T&A, 19 (10 males, 53%) children (17 HbSS, 89.5%; 2 HbSC, 10.5%) were
retained in the final analysis. Median age at surgery was 6 years (range 3.5–8). Three (16%) out of 19
children were already on HU before undergoing T&A (HU started at least 1 year prior to the surgery),
while 1 (5%) out of 19 was started on exchange blood transfusion (EBT) 17 months before, because of
abnormal transcranial doppler velocities. One child (5%) had adenoidectomy alone, while 18 (95%) out of
19 underwent T&A. Indication to T&A was based in most cases (15 (79%) out of 19) on the presence of
SDB symptoms with a 3% ODI ⩾3 [15]. In a minority of children T&A was performed for severe
adenotonsillar hypertrophy with SDB symptoms according to the indication of the ear, nose and throat
specialist (2 (10.5%) out of 19). Finally, in two children (10.5%) it was not possible to establish with
certainty from medical records the indication to T&A because of missing data.
All participants received a pre-operative blood transfusion in order to achieve a target Hb level of
90–100 g·L−1 [18]. One child presented with acute upper airway obstruction post-operatively and required
a 48-h admission in the paediatric intensive care unit. No other intra-operative and post-operative major
complications were reported. Other baseline features are shown in table 1.
Nocturnal oximetry before and after T&A
Night-time oximetry studies were recorded at a median time interval of 5.5 months before (range
4.5–10.5) and 7.5 months after the surgery (range 6.3–10.8) (table 2).














Grade I 1 (5%)
Grade II 2 (10.5%)
Grade III 7 (37%)
Grade IV 7 (37%)
Snoring ⩾3 times a week+ 19 (100%)
Data are presented as n (%) or median (interquartile range), unless otherwise stated. Hb: haemoglobin;
HU: hydroxyurea; EBT: exchange blood transfusion. #: Diagnosis was made in compliance with Global
Initiative for Asthma guidelines [19]; ¶: according to tonsil grading scale by Brodsky [34]; +: according to
the current definition of snoring in sleep-disordered breathing [20].
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After T&A, there was a significant increase of mean overnight SpO2 (p=0.001) and nadir SpO2 (p=0.004), as
well as an improvement of 3% ODI (p=0.003) (table 2). In children with SDB and 3% ODI⩾3 (15 (79%)
out of 19), improvements in overnight oxygen saturation parameters were comparable to those of the
whole sample (data not shown). The proportion of patients with a 3% ODI⩾3 at nocturnal oximetry
passed from 79% (15 out of 19) to 37% (7 out of 19) (p=0.02), whereas that of children with a mean
overnight oximetry <94% decreased from 42% (8 out of 19) to 26% (5 out of 19) (p=0.49).
SCD-related complications before and after T&A
Following the surgery, the mean annual rate of ACS dropped from 0.6±1.22 to 0.1±0.2 per patient per year
(p=0.03), while the mean cumulative rate of hospitalisation from every cause and the incidence of hospital
admissions for VOE were not affected (figure 1).
Discussion
In this study, for the first time, we showed that children with SCD who underwent T&A had significantly
reduced rates of ACS episodes. Hospital admissions from all causes did not significantly change at 1-year
follow-up after the surgery. We also report that children with SCD who underwent T&A had improved
overnight SpO2, as previously described [12, 13].
Sleep abnormalities are characterised by intermittent hypoxia that may increase oxidative stress activating
inflammatory pathways [21, 22]. Moreover, oxygen desaturation promotes HbS polymerisation and RBC
sickling, which in turn causes microvascular occlusion, inflammation, haemolysis and tissue hypoxia,
potentially triggering SCD-related acute and chronic manifestations [23]. Given these factors, the increase
in SCD severity would be expected in patients with SDB and nocturnal hypoxaemia. However, some
previous studies only showed an association between nocturnal hypoxaemia and central nervous system
complications [8, 24], whereas others failed to demonstrate an increased risk of ACS [9] and VOE [9, 10]
in relation to a low night-time SpO2.
Our results support the hypothesis that T&A improves overnight blood oxygenation and intermittent
oxygen desaturation in children with SCD and upper airway obstruction, consistently with previous
TABLE 2 Effect of tonsillectomy and adenoidectomy (T&A on overnight oximetry (SpO2) of
children with sickle cell disease (n=19)
Before T&A After T&A p-value
Overnight SpO2 %
# 93.0±3.6 95.3±2.8 0.001
Nadir overnight SpO2 %
# 83.0±7.1 88±4.1 0.004
% time SpO2 <90%
¶ 0.3 (0–6) 0.1 (0–2) 0.107
Nocturnal 3% ODI¶ 5.7 (3.6–7.8) 1.8 (1.2–6.0) 0.003
Data are presented as mean±SD or median (interquartile range), unless otherwise stated. #: Passed the
normality test: analysed by paired t-test; ¶: not passed the normality test: analysed by Wilcoxon
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FIGURE 1 Mean annual rates of hospital admission for vaso-occlusive pain episodes (VOEs), acute chest
syndrome (ACS) and for “all causes” in 19 children with sickle cell disease during the 12 months before and
after tonsillectomy and adenoidectomy (T&A). Groups were compared through a paired t-test.
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retrospective analysis [12–14, 25]. In particular, significant reduction of snoring and daytime somnolence,
with reported better school attendance and objective improvement in sleep study parameters were
previously observed after T&A in a small cohort of eight children with upper airway obstruction and
SCD [25]. Our study showed for the first time that T&A was associated with a significant reduction in the
number of ACS events per patient·yr−1. Previously, FINCH et al. [13] did not find a reduced incidence of
ACS and VOE in children with SCD after T&A, but only 13 children were evaluated, fewer than in our
cohort. More recently, FARRELL et al. [12] observed a drop in the rate of overall emergency department
visits per patient per year in the 12 months following T&A. In our study we did not recorded unscheduled
emergency department visits, but this intervention did not result in a significant reduction of hospital
admission rate. Moreover, contrary to the present study, FARRELL et al. [12] reported that ACS had a
similar incidence pre- and post-surgery. In the presence of low alveolar oxygen tension, abnormal sickle
RBC tend to stick together and to adhere to leukocytes and vascular endothelium. This process
causes vaso-occlusion, inflammation and, in the pulmonary circulation, it may cause hypoxic
vasoconstriction [26]. As these mechanisms are among the triggers of ACS episodes [27], we hypothesised
that the relative increase in blood oxygenation that occurred in our cohort after T&A, had a protective role
against RBC sickling in the pulmonary microcirculation, contributing to prevent ACS. Further verification
on prospective longitudinal data or randomised controlled trials, with a sample specifically powered for
this outcome (the impact of T&A on ACS incidence) and a longer follow-up, is warranted.
In non-SCD children with OSA it was shown that the restoration of an adequate and stable overnight SpO2
may also prevent the risk of cardiovascular complications, neurocognitive impairment and poor school
performance [28, 29]. The reduction of ODI after T&A seen in our SCD cohort, therefore, might result in
a decreased likelihood of future OSA-related morbidities.
The present study confirmed recently reported low rates of peri-operative complications in children with
SCD undergoing T&A [12]. In general, surgery in SCD patients implies a significantly increased risk due
to anaemia, hypoxia and possible post-surgical bleeding [30, 31]. However, since 1995 pre-operative
transfusion protocols have been largely implemented with a dramatic decrease of post-surgical
complications [32–35]. Currently, blood transfusion is universally recommended for SCD patients with
low Hb level (<90 g·L−1) undergoing a mild to moderately severe surgical procedure and/or general
anaesthesia [18]. Accordingly, all our children had an elective blood transfusion prior to T&A to increase
Hb level to a target level of 90–100 g·L−1 [18]. The low frequency of peri-operative complications indicates
that T&A has a good safety profile in children with SCD when performed in centres experienced in the
management of this condition.
Among the limitations of this study, because complete polysomnography results, including
apnoea–hypopnoea index (AHI), were available only in a minority of patients (5 (26%) out of 19), we
could not properly identify children with OSA, even if the combination of SDB symptoms and 3% ODI⩾3
(that was the main indication to T&A in our cohort of SCD patients) was shown to be highly predictive of
an AHI>5 in children [15]. However, as the use of 3% ODI⩾3 in combination with SDB to define OSA
came from a cohort of otherwise healthy paediatric patients, this criterion may lead to a misinterpretation
of the results, as SCD children have a higher prevalence of hypoxaemia than healthy children, and several
studies suggested that this condition may not be due to OSA alone [36]. This might also explain why the
3% ODI did not improve in all patients after T&A.
Moreover, nocturnal hypoxia may also be present in several major cardiovascular complications of SCD,
including pulmonary hypertension and higher end-diastoclic left ventricular diameters [37]. As per the
recommendations [38], children with SCD usually undergo routine echocardiography screening every
1–3 years in the absence of further indication, and in our cohort none of the enrolled patients developed
any cardiac complications within the studied period. However, due to the retrospective design of this
study, it was not possible to specifically compare pre- and post-echocardiography measures.
We excluded SCD patients who were started on HU or supplemental oxygen therapy during the
post-surgery follow-up, as it was not possible to control for these important confounders. However, by
doing so, our sample became less representative of the general SCD population, where most severe patients
are usually initiated on HU.
A strength of this study was that, despite the retrospective design, we could compare pre- and post-T&A
overnight oximetry data that were collected when patients were at steady state, with tests performed in the
same environment, using the same methodology and device. Moreover, the availability of detailed
digitalised medical history information for each patient allowed a precise measure of the incidence of
SCD-related complications and overnight oximetry in the year prior to and after T&A.
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In summary, this study showed that children with SCD who have SDB and nocturnal hypoxaemia may
benefit from T&A in terms of improved overnight SpO2 and decreased incidence of ACS episodes.
Moreover, our study confirmed that T&A in paediatric patients with SCD has a satisfactory safety profile
when performed in experienced centres. Future studies should further clarify the impact of T&A on the
incidence of SCD-related complications in prospective cohorts with a longer follow-up and adequate
control for confounding.
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